CHANGE IN CONTROL SEVERANCE AGREEMENTChange in Control Severance Agreement • February 5th, 2014 • Immunogen Inc • Pharmaceutical preparations • Massachusetts
This Agreement is entered into as of the 30th day of December, 2013 (the “Effective Date”) by and between ImmunoGen, Inc., a Massachusetts corporation (the “Company”), and David B. Johnston (the “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • February 5th, 2014 • Immunogen Inc • Pharmaceutical preparations • Massachusetts
This Employment Agreement (the “Agreement”), dated as of December 30, 2013 (the “Effective Date”), is made by and between ImmunoGen, Inc., a Massachusetts corporation (the “Company”), and David B. Johnston (“Executive”). This Agreement is intended to confirm the understanding and set forth the agreement between the Company and Executive with respect to Executive’s employment by the Company. In consideration of the mutual promises and covenants contained in this Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are hereby mutually acknowledged, the Company and the Executive hereby agree as follows:
FIRST AMENDMENT TO LEASE AGREEMENTLease Agreement • February 5th, 2014 • Immunogen Inc • Pharmaceutical preparations
This FIRST AMENDMENT TO LEASE AGREEMENT (the “Amendment”) dated this 9th day of December, 2013 (the “Effective Date”), is made by and between INTERCONTINENTAL FUND III 830 WINTER STREET, LLC, a Massachusetts limited liability company (the “Landlord”), and IMMUNOGEN, INC., a Massachusetts corporation (the “Tenant”).
CONFIDENTIAL TREATMENT REQUESTED FIRST AMENDMENT TO AGREEMENTSMulti-Target Agreement and License Agreement • February 5th, 2014 • Immunogen Inc • Pharmaceutical preparations
This First Amendment to Agreements (the “First Amendment”) is made effective as of the date of the last signature below (the “First Amendment Effective Date”) by and between ImmunoGen, Inc., a Massachusetts corporation (“ImmunoGen”), with its principal place of business being 830 Winter Street, Waltham, Massachusetts 02451, USA, and Eli Lilly and Company, an Indiana corporation (“Lilly”), with its principal place of business at Lilly Corporate Center, Indianapolis, Indiana 46285. ImmunoGen and Lilly are sometimes hereinafter referred to individually as a “Party” and collectively as the “Parties.”
